Cardio Flow
St. Paul, US · Founded 2010 · Delaware corporation
Cardio Flow develops FreedomFlow, an atherectomy platform used by physicians to treat peripheral artery disease (PAD) across a range of vessel diameters. The system uses diamond-coated rotating spheres on a driveshaft to clear complex arterial lesions and is intended for hospitals, ambulatory surgery centers, and office-based labs.
BiotechHardwareHealthtechMedical Devices
Founders & leadership
MJ
Michael J. KallokExecutive
Board
GM
Gary M. PetrucciBoard director
SC
Steven C. SimonBoard director
GM
Gary McCordBoard director
DB
David BrinkBoard director
Reported raises · per SEC filings
Form D private placements$14.8M disclosed across 12 of 14 rounds · 2015–2024
▶$400KraisedJun 2024 · 3 investors · Other Health CareRule 506(b)
▶$400KraisedJun 2024 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Gary McCordDirector
- Steven SimonDirector
- Gary PetrucciDirector
- David BrinkDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $400K
- Proceeds to insiders
- $370K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedSep 2023 · 2 investors · Other Health CareRule 506(b)
▶$100KraisedSep 2023 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David BrinkDirector
- Gary McCordDirector
- Steven SimonDirector
- Gary PetrucciDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaDirector
- Offering amount
- $2M
- Amount sold
- $100K
- Minimum investment
- $25K
- Proceeds to insiders
- $160K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedMay 2023 · 12 investors · Other Health CareRule 506(b)
▶$1.1MraisedMay 2023 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Gary PetrucciDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaDirector
- Steven SimonDirector
- David BrinkDirector
- Gary McCordDirector
- Offering amount
- $2.5M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- Proceeds to insiders
- $210K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedSep 2021 · 3 investors · BiotechnologyRule 506(b)
▶$200KraisedSep 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary McCordDirector
- Steven SimonDirector
- David BrinkDirector
- Gary PetrucciDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaDirector
- Offering amount
- $12M
- Amount sold
- $200K
- Minimum investment
- $25K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedApr 2021 · 12 investors · BiotechnologyRule 506(b)
▶$2.7MraisedApr 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary PetrucciDirector
- Jihad MustaphaDirector
- David BrinkDirector
- Michael KallokExecutive Officer, Director
- Steven SimonDirector
- Gary McCordDirector
- Offering amount
- $4.5M
- Amount sold
- $2.7M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$489KraisedJan 2021 · 7 investors · BiotechnologyRule 506(b)
▶$489KraisedJan 2021 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael KallokExecutive Officer, Director
- Gary PetrucciDirector
- Jihad MustaphaDirector
- David BrinkDirector
- Gary McCordDirector
- Steven SimonDirector
- Offering amount
- $650K
- Amount sold
- $489K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedMay 2020 · 7 investors · BiotechnologyRule 506(b)
▶$1.2MraisedMay 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary McCordDirector
- Gary PetrucciDirector
- Steven SimonDirector
- David BrinkDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaDirector
- Offering amount
- $3.5M
- Amount sold
- $1.2M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$360KraisedFeb 2020 · 2 investors · BiotechnologyRule 506(b)
▶$360KraisedFeb 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DAVID BRINKDirector
- STEVEN SIMONDirector
- GARY PETRUCCIDirector
- JIHAD MUSTAPHADirector
- GARY MCCORDDirector
- MICHAEL KALLOKExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $360K
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapHeartFlow22 shared keywordsHeartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD). Its platform, Heartflow One, is used by cardiologists and clinicians to guide diagnosis and treatment decisions for patients.
American Endovascular18 shared keywordsOutpatient centers for treatment of peripheral artery disease.
Clearflow14 shared keywordsClearFlow develops PleuraFlow Active Clearance Technology, a device that maintains chest drain patency after cardiac surgery to reduce Retained Blood Syndrome complications, along with products for sternal fixation and reconstruction following sternotomy. The products are used in ICU and surgical settings for post-cardiac-surgery patient care.
Corflow13 shared keywordsCorFlow develops the Controlled Flow Infusion (CoFI) System, a catheter-based device for cardiologists to diagnose microvascular obstruction in heart attack (STEMI) patients and deliver therapeutic agents directly into the vasculature during PCI procedures. The medical device integrates into existing catheterization workflows to detect MVO and support cardiac treatment.
Texas Endovascular12 shared keywordsTexas Endovascular is a network of clinics staffed by board-certified interventional radiologists offering minimally invasive, image-guided treatments for conditions including uterine fibroids, vein disease, peripheral artery disease, enlarged prostate, hemorrhoids, and joint pain. It serves patients across the Greater Houston and Dallas–Fort Worth areas.
Medflow12 shared keywordsMedFlow is an AI-powered clinical operations platform that automates outpatient care workflows such as scheduling, patient prep, care coordination, and closing care gaps, with bidirectional integration into EHRs like athenaOne, HIEs, labs, and engagement tools. It serves healthcare providers and practices, including primary care and specialty practices, to support population health operations and performance-based reimbursement.
Companies competing with Cardio Flow for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cardio Flow do?
- Cardio Flow develops FreedomFlow, an atherectomy platform used by physicians to treat peripheral artery disease (PAD) across a range of vessel diameters. The system uses diamond-coated rotating spheres on a driveshaft to clear complex arterial lesions and is intended for hospitals, ambulatory surgery centers, and office-based labs.
- How much funding has Cardio Flow raised?
- Cardio Flow has disclosed $14.8M raised across 12 of its 14 known rounds.
- Where is Cardio Flow headquartered?
- Cardio Flow is headquartered in St. Paul, US.